Tocilizumab in COVID-19 Treatment: A Cost-Burden in Low- and Middle-Income Countries

The outbreak of Corona Virus Disease-19 (COVID-19) in Wuhan, China caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was declared a ‘pandemic disease’ by the World Health Organization (WHO), and the application of tocilizumab in the down regulation of interleukin-6 (IL-6), a potential disease worsening factor, was hypothesized in a published article by Zhang and colleagues (1), and tocilizumab has introduced as a promising treatment option for COVID-19.